Country: Canada
Language: English
Source: Health Canada
CARPROFEN
ZOETIS CANADA INC
50MG
SOLUTION
CARPROFEN 50MG
SUBCUTANEOUS
20ML
Prescription
DOGS
Active ingredient group (AIG) number: 0137034004
APPROVED
2004-07-08
DIN 02255693 _CARPROFEN INJECTABLE SOLUTION _ VETERINARY USE ONLY Non-steroidal anti-inflammatory For subcutaneous use in dogs only. DESCRIPTION: Rimadyl injectable solution is a sterile solution containing carprofen, a non-steroidal anti- inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen. The chemical name for carprofen, a substituted carbazole, is (±)-6-chloro-α- methylcarbazole-2-acetic acid. The empirical formula is C 15 H 12 NO 2 CI and molecular weight 273.72. The chemical structure of carprofen is: Each mL of Rimadyl injectable solution contains 50.0 mg of carprofen as the medicinal ingredient and 10.0 mg of benzyl alcohol as the preservative. CLINICAL PHARMACOLOGY: Carprofen is a non- narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models. 1 The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. 2 The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. The specificity of a particular NSAID for COX-2 versus COX-1 may vary from species to species. 3 In an _in vitro _study using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1. 4 Clinical relevance of these data has not been shown. Carprofen has also been shown to inhibit the release of several prostaglandins in two inflammatory cell systems: rat polymorphonuclear leukocytes (PMN) and human rheumatoid synovial cells, indicating inhibition of acute (PMN system) and chronic (synovial cell system) inflammatory reactio Read the complete document